Otsuka reported a clinical win for centanafadine in patients with ADHD and comorbid anxiety. Top-line results from a dedicated Phase IIIb study met the primary endpoint, defined as symptom score improvements on the Adult Investigator Symptom Rating Scale at week 8 versus placebo. The candidate is positioned as a once-daily, non-stimulant therapy targeting attention deficit hyperactivity disorder via a mechanism distinct from stimulant approaches. The Phase IIIb design specifically addresses the comorbid anxiety population, where tolerability and efficacy profiling can be more complex. The readout strengthens centanafadine’s late-stage momentum ahead of any subsequent regulatory interactions tied to labeling breadth in ADHD with anxiety comorbidity.